Liukaityte R, Stenberg VY, Kleinauskas A, Juzenas P, Urbanucci A, Juzeniene A(2025) Combination of PSMA targeting alpha-emitting radioligand [212Pb]Pb-AB001 with BET bromodomain inhibitors in in vitro prostate cancer models Med Oncol, 42(8), 362 DOI 10.1007/s12032-025-02925-9, PubMed 40694184
Severson TM, Minnee E, Zhu Y, Schuurman K, Nguyen HM, Brown LG, Hakkola S, Menezes R, Gregoricchio S, Kim Y, Kneppers J, Linder S, Stelloo S, Lieftink C, van der Heijden MS, Nykter M, van der Noort V, Sanders J, Morris B, Jenster G, van Leenders GJ, Pomerantz M, Freedman ML, Beijersbergen RL, Urbanucci Aet al.(2025) Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer Cell Rep Med, 6(7), 102215 DOI 10.1016/j.xcrm.2025.102215, PubMed 40609538
Bouska A, Zhang W, Sharma S, Holte H, Shah RA, Lone WG, Soma MA, Yang R, Liu X, Mehmood S, Chawla RS, Cappelli LV, Fiore D, Gong Q, Heavican-Foral TB, Cannatella JJ, Amador C, Arif A, Smith LM, Lim ST, Ong CK, Feldman AL, Du MQ, Perry AM, de Leval Let al.(2025) Integrative Genomic and Transcriptomic Analysis Reveals Targetable Vulnerabilities in Angioimmunoblastic T-Cell Lymphoma Am J Hematol(in press) DOI 10.1002/ajh.27736, PubMed 40510016
